Vintage Zwarte Windmolen Tijdens Zonsondergang


In this newsletter we are happy to announce:


Ø New product: IQ Perm, erythrocyte permeabilization buffer


Ø Publication on clinical presentation of patients with adverse effects towards AstraZeneca vaccine using the HITAlert™


Ø Webinar on consquences of the European IVDR regulation on 15th of June: What will change for manufacturers, distributors and diagnostic laboratories?


Ø Publication from our Research and Development department on Circulating Guanylate-Binding-Protein-1 (GBP-1) in healthy and preeclamptic women



New product

IQ Perm, erythrocyte permeabilization buffer



This buffer can be used in combination with our anti-hemoglobin antibodies, such as anti-hemoglobin S, anti-hemoglobin F, and anti-panHb (HbA alpha chain), conjugated with various fluorochromes.


IQ Perm is used to permeabilize cells prior to intracellular staining of erythrocytes, but is also suitable for permeabilization of leukocytes. It should be applied to fixed cells prior to antibody staining, followed by flow cytometric analysis.





Publication HITAlert



In rare cases, adverse reactions are observed following vaccination with the AstraZeneca vaccine (Vaxzevria). The vaccine induced thrombosis and thrombocytopenia (VITT) resembles the symptoms of heparin induced thrombocytopenia (HIT). Therefore, several countries recommend to follow the screening procedure for HIT when this adverse reaction to the vaccine is observed.

The UCLH just
published a study in which they aim to gain a better understanding of the described clinical syndrome of VITT. For this purpose, they used the diagnostic screening procedure of HIT, including assessment of antibodies using ELISA and a functional assay, in this case IQ Products’ HITAlertTM kit.

Visit our website page
here for more information about the HITAlertTM kit.








Webinar on IVDR: 15th of June



The new Regulation (EU) 2017/746 on In Vitro Diagnostic Medical Devices Regulation (IVDR) will become effective in Europe on 26th of May 2022. The IVDR will replace the current Directive 98/79/EC (IVDD) and has major impact on all companies and institutes dealing with IVD CE products.


The full IVDR requirements are extensive, therefore, we will organize a webinar providing an overview of the key points of the new regulation and an opportunity for a discussion on the implementation.


The webinar will take place on the 15th of June. We have reserved 2 time slots: 10:00h and 16:00h Central European time (CET). If you would like to participate in the webinar, please send an email to to receive an invitation.




Publication from our R&D department



Our R&D department studies early biomarkers during pregnancy to assess the risk for pregnancy related disorders, in this case pre-eclampsia. The results of one of their studies have just been published!


In this study, they looked at Guanylate-Binding-Protein-1 (GBP-1) in peripheral blood during healthy and preeclamptic pregnancies. The publication describes that plasma GBP-1 levels do not increase in early or late onset pre-eclamptic pregnancies, while it increases during healthy pregnancies as compared to non-pregnant women.


Do you want to learn more? Check out the full paper here




Upcoming events 2021*



Sept 2021 -  AACC, Atlanta, Georgia, USA

Nov 2021  -  NVC/NVKC, Zwolle, The Netherlands

*Unfortunately, many organizations have been forced to cancel or postpone their events. As soon as we have more information on new dates, they will be posted on our website.




Thank you for your interest in IQ Products!



Address details


Rozenburglaan 13a

9727 DL Groningen



Technical questions:




How to order at IQ Products:



By e-mail:


By fax:

+31 (0)50 57 57 002


By phone:

+31 (0)50 57 57 000



Find your local distributor online:



Follow us: